Botulinum Toxin Injections for Neurogenic Detrusor Overactivity Periprocedural Care
- Author: Pamela I Ellsworth, MD; Chief Editor: Edward David Kim, MD, FACS more...
Injection of botulinum toxin A may be performed by means of either rigid or flexible cystoscopy. Various different endoscopic needles may be used for the injection, in particular ultrafine 4-mm flexible needles that may be passed through the flexible cystoscope. Besides the 4-mm flexible needle, the needle used for collagen injection and the needle used for dextranomer or hyaluronic acid injection have also been used for this procedure.
Botulinum toxin A
OnabotulinumtoxinA (ie, BOTOX) is supplied in single-use 100-U and 200-U vials. Before injection, each vacuum-dried vial must be reconstituted (see below). After reconstitution, onabotulinumtoxinA should be administered within 24 hours. Reconstituted onabotulinumtoxinA should be stored in a refrigerator at a temperature of 2-8° C.
In treating adult patients for 1 or more indications, the maximum cumulative dose generally should not exceed 360 U in a 3-month period. The recommended treatment dose of onabotulinumtoxinA is 200 U per treatment, divided into 30 injections of 1 mL.
Options for reconstitution
Reconstitution of onabotulinumtoxinA may be accomplished in 1 of 2 ways. The first is to reconstitute a 200-U vial by adding 6 mL of 0.9% sterile nonpreserved saline solution, mixing gently, and withdrawing 2 mL from the vial into each of 3 separate 10-mL syringes. Reconstitution is completed by adding 8 mL of 0.9% nonpreserved saline solution into each of the 10-mL syringes and mixing gently. Each of the 3 syringes will then contain 10 mL (about 67 U of onabotulinumtoxinA), for a total of 200 U of reconstituted onabotulinumtoxinA.
The second option is to reconstitute a pair of 100-U vials by placing 6 mL of 0.9% nonpreserved saline solution into each one, mixing the vials gently, withdrawing 4 mL from each of the 2 vials into 2 separate 10-mL syringes, and withdrawing the remaining 2 mL from each vial into a third 10-mL syringe. Reconstitution is completed by adding 6 mL of 0.9% nonpreserved saline into each of the 10-mL syringes and mixing gently. As with the first option, each of the 3 syringes will then contain 10 mL (about 67 U of onabotulinumtoxinA), for a total dose of 200 U.
Intradetrusor injection of onabotulinumtoxinA may be performed via flexible or rigid cystoscopy and may involve either local anesthesia (with or without sedation) or general anesthesia, depending on the patient’s sensory status, anxiety level, and risk of autonomic dysreflexia. In patients who are at risk for autonomic dysreflexia or have experienced autonomic dysreflexia with previous bladder filling, consideration of monitoring or pretreatment may be indicated.
Patients undergoing injection of botulinum toxin A should not have an acute urinary tract infection. It is recommended that prophylactic antibiotics (except aminoglycosides, because of the potential for drug interactions) be administered 1-3 days before treatment, on the day of treatment, and 1-3 days after treatment.
Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005 Sep. 174(3):977-82; discussion 982-3. [Medline].
Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005 Jul. 66(1):94-8. [Medline].
Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005 Jul. 174(1):196-200. [Medline].
Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004 Jul. 172(1):240-3. [Medline].
Kim SW, Choi JH, Lee YS, Han SW, Im YJ. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. Urology. 2014 Dec. 84 (6):1480-4. [Medline].
Peyronnet B, Castel-Lacanal E, Manunta A, Roumiguié M, Marque P, Rischmann P, et al. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin. Int J Urol. 2015 Sep 22. [Medline].
Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011 Apr. 185(4):1344-9. [Medline].
Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006 Mar. 49(3):528-35. [Medline].